

Kidney Cancer GComm 1 – minutes

Kidney Cancer update – committee meeting 1 minutes

**Date:** 13/12/23

**Location:** Virtual

**Minutes:** Draft

<b>Committee members present:</b>		
<b>Baljit Singh</b>	<b>Committee Chair</b>	Present for items 1 - 10
Axel Bex	Urological Surgeon	Present for items 1 - 10
Janet Brown	Medical Oncologist	Present for items 1 - 10
Lisa Browning	Histopathologist	Present for items 1 - 8
Amarnath Challapalli	Clinical Oncologist (General)	Present for items 1 - 10
Amy Clifford	Clinical Oncologist (SABR)	Present for items 3 - 10
David Cullen	Urology Cancer Nurse	Present for items 1 - 10
Stuart Evans	Oncology Pharmacist	Present for items 1 - 10
Ana Filipa Semedo	Oncology Cancer Nurse	Present for items 1 - 10
Geraldine Fox	Lay Member	Present for items 1 - 10
Tze Min Wah	Interventional Radiologist	Present for items 1 - 10
David Mole	Nephrologist	Present for items 1 - 10
Vishal Patil	Anaesthetist	Present for items 1 - 10
Ankit Rao	Medical Oncologist	Present for items 2 - 10
Sandeep Singh Randhawa	General Practitioner	Present for items 1 - 10
Grant Stewart	Topic Adviser	Present for items 1 - 5
Maxine Tran	Urological Surgeon	Present for items 1 - 8
Sam Withey	Diagnostic Radiologist	Present for items 1 - 10
James Whitworth	Clinical geneticist	Present for items 1 - 10
Rose Woodward	Lay Member	Present for items 1 - 10

<b>In attendance:</b>		
Lucy Beggs (LB)	NICE Technical Adviser, Health Economics	Present for items 1 - 10
Sarah Boyce (SB)	NICE Senior Technical Analyst	Present for items 1 - 10
Melanie Carr	NICE Senior Technical Analyst – Quality Indicators	Present for items 1 - 10
Victoria Carter	NICE Implementation Support Manager	Present for items 1 - 10
Becky Chadwick (BC)	NICE Project Manager	Present for items 1 - 10
Lindsay Claxton	NICE Technical Adviser, Health Economics	Present for items 1 - 10
Amy Finnegan	NICE Senior Information Specialist	Present for items 1 - 10

## Kidney Cancer GComm 1 – minutes

Craig Grimes (CG)	NICE Technical Adviser – Quality Indicators	Present for items 1 - 10
Lina Manounah ( <i>Observing</i> )	NICE Technical Analyst	Present for items 1 - 6
Jean Ryan	NICE Programme Manager	Present for items 1 - 10
Katherine Saxby (KS)	NICE Medicines Adviser	Present for items 1 - 10
Sarah Scott ( <i>Observing</i> )	NICE Public Involvement Adviser	Present for items 1 - 2
Steve Sharp (SS)	NICE Technical Adviser	Present for items 1 - 10
Hannah Tebbs	NICE Technical Analyst, Health Economics	Present for items 1 - 10
Yuanyuan Zhang	NICE Technical Analyst, Health Economics	Present for items 1 - 10

### Apologies:

John Connelly	Lay Member
James Hall	NICE Content Editor
Kate Kelley	NICE Associate Director

### 1. Welcome and objectives for the meeting

The Chair (BS) welcomed the committee members and NICE attendees to the first committee meeting for the update to the NICE Kidney Cancer guideline.

BS informed attendees that apologies had been received as noted above. BS asked all committee members to verbally declare any new interests.

BS then outlined the aims and objectives for the meeting.

### 2. Overview of guideline scope and development timeline

BS introduced NICE Technical Adviser Steve Sharp (SS), who gave an overview of the guideline scope and the timeline and schedule of meetings during development for the update.

BS thanked SS for his presentation.

### 3. Introduction to protocol development

BS introduced NICE Senior Technical Analyst Sarah Boyce (SB), who gave an overview of the review protocol development process and the draft protocols for the kidney cancer guideline.

BS thanked SB for her presentation and the committee for their input.

### 4. Non-pharmacological management: protocols 3a, 3b, 4a, 6b (Part 1)

NICE Senior Technical Analyst Sarah Boyce (SB) and NICE Technical Analyst Fernando Zanghelini (FZ) presented on non-pharmacological management for kidney cancer covered in protocols 3a, 3b, 4a and 6b.

BS thanked SB and FZ for their presentation and the committee for their input.

#### **5. Non-pharmacological management: protocols 3a, 3b, 4a, 6b (Part 2)**

Following a short break, SB and FZ continued their presentation on non-pharmacological management, covering protocols 3a, 3b, 4a and 6b.

BS thanked SB and FZ for their presentation and the committee for their input.

#### **6. Non-pharmacological management: protocols 3a, 3b, 4a, 6b (Part 3)**

SB and FZ continued their presentation on non-pharmacological management, covering protocols 3a, 3b, 4a and 6b.

BS thanked SB and FZ for their presentation and the committee for their input.

#### **7. Introduction to health economics and prioritisation process for economic modelling**

BS introduced NICE Technical Adviser, Health Economics, Lucy Beggs (LB) who gave the committee a brief introduction to health economics and how cost-effectiveness is used in NICE guidelines, followed by an overview of the prioritisation process for economic modelling. LB then invited comments and questions from the committee.

BS thanked LB for her presentation and the committee for their input.

#### **8. Pharmacological management: Protocol 3c Localised RCC, Protocol 4b Locally advanced RCC, Protocol 6a Metastatic RCC (including visual summary)**

SB and FZ presented on pharmacological management, covered in protocols 3c, 4b and 6a.

BS also introduced NICE Medicines Adviser Katherine Saxby (KS) who gave a high-level overview on the development of a treatment options summary for advanced kidney cancer. The aim of the treatment options summary is to provide a visualisation of the treatment pathway that is useful and useable by including placement of technology appraisals and NHS England commissioning policy.

BS thanked SB, FZ and KS for their presentations and the committee for their input.

#### **9. Quality standard overview**

BS introduced NICE Technical Adviser, Quality Indicators Craig Grimes (CG), who gave the committee an overview of the plan to develop and publish a NICE quality standard for kidney cancer at the same time as the kidney cancer guideline update.

BS thanked CG for his presentation and the committee for their comments.

#### **10. AOB, Summary and next steps**

## Kidney Cancer GComm 1 – minutes

BC gave the committee an overview of the next steps for the guideline, and thanked the committee for their contributions. BS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, BS brought the meeting to a close.

**Date of next meeting:** 30/01/2024

**Location of next meeting:** Virtual